Therapy-related myelodysplasia and acute myeloid leukemia.
Therapy-related myelodysplasia and acute myeloid leukemia.
复制标题
DOI：
10.1053/j.seminoncol.2013.09.013
复制
发表时间：
2013-12
影响因子：
4
通讯作者：
Bhatia S
中科院分区：
文献类型：
--
作者：
Bhatia S
治疗相关性白血病（t-MDS/AML）是用于治疗各种原发性恶性肿瘤（包括霍奇金淋巴瘤（HL）和非霍奇金淋巴瘤（NHL）、急性淋巴细胞白血病（ALL）、肉瘤以及卵巢癌和睾丸癌）的常规放化疗的常见并发症。t-MDS/AML的中位发展时间为3至5年，第一个十年后风险显着降低。t-MDS/AML是HL或NHL自体造血细胞移植（HCT）后非复发死亡的主要原因。与常规治疗相比，HCT后t-MDS/AML的风险程度更高，潜伏期更短。两种类型的t-MDS/AML的识别取决于病因治疗暴露：烷化剂/放射相关型和拓扑异构酶II相关型。t-MDS/AML发生风险的个体间差异表明遗传变异在遗传毒性暴露易感性中的作用。用常规疗法治疗t-MDS/AML与一致的不良预后相关，中位生存期为6个月。由于常规化疗反应差，建议使用同种异体HCT。目前的研究重点是制定风险预测和减少风险的战略。
Therapy-related leukemia (t-MDS/AML) is a well known complication of conventional chemoradiotherapy used to treat a variety of primary malignancies including Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), sarcoma, and ovarian and testicular cancer. The median time to development of t-MDS/AML is 3 to 5 years, with the risk decreasing markedly after the first decade. t-MDS/AML is the major cause of non-relapse mortality after autologous hematopoietic cell transplantation (HCT) for HL or NHL. The magnitude of risk of t-MDS/AML is higher, and the latency is shorter after HCT, compared to conventional therapy. Two types of t-MDS/AML are recognized depending on the causative therapeutic exposure: an alkylating agent/radiation-related type and a topoisomerase II inhibitor-related type. Interindividual variability in the risk for development of t-MDS/AML suggests a role for genetic variation in susceptibility to genotoxic exposures. Treatment of t-MDS/AML with conventional therapy is associated with a uniformly poor prognosis, with a median survival of 6 months. Because of the poor response to conventional chemotherapy, allogeneic HCT is recommended. Current research is focused on developing risk prediction and risk reduction strategies.
登录
查看更多内容
影响因子：
10.4
作者：
Au, William W;Salama, Salama A;Sierra-Torres, Carlos H
通讯作者：
Sierra-Torres, Carlos H
影响因子：
5.3
作者：
CALDECOTT, KW;MCKEOWN, CK;THOMPSON, LH
通讯作者：
THOMPSON, LH
影响因子：
20.3
作者：
Bhatia, S;Sather, HN;Robison, LL
通讯作者：
Robison, LL
影响因子：
4.8
作者：
Bishop, DK;Ear, U;Shinohara, A
通讯作者：
Shinohara, A
影响因子：
29.4
作者：
BRENTNALL, TA;RUBIN, CE;RABINOVITCH, PS
通讯作者：
RABINOVITCH, PS